Educational information, not medical advice — ask your doctor or midwife.
(Based on double-blind, placebo-controlled clinical trials where available and supported by preclinical and translational research)
KPV is a short tripeptide fragment derived from the alpha-melanocyte-stimulating hormone (α-MSH). It exhibits potent anti-inflammatory, antioxidant, and antimicrobial effects, particularly within the gut, skin, and immune system. KPV has gained attention for treating inflammatory bowel diseases (IBD), skin inflammation, wound healing, and systemic inflammatory conditions without immunosuppressive side effects.
KPV works by:
Unlike corticosteroids, KPV reduces inflammation without suppressing immunity, making it suitable for autoimmune, gut, and skin disorders.
KPV is not produced independently but is cleaved from α-MSH, which plays a role in controlling inflammation and melanogenesis. Deficiency or imbalance in melanocortin signaling can contribute to:
KPV can help restore immune regulation and tissue repair capacity without toxic suppression of immune defenses.
KPV was first identified in the late 1990s to early 2000s as the key anti-inflammatory region of α-MSH. Research expanded in the 2010s into gut and skin applications. It is currently in clinical development and off-label use in integrative and peptide therapy circles for inflammation control and mucosal healing
KPV is one of the most promising natural peptide therapies for inflammation, offering targeted support for gut health, skin conditions, immune modulation, and tissue repair. Its excellent safety profile, non-suppressive action, and ability to calm autoimmune flares without toxicity make it an emerging star in naturopathic, functional, and regenerative medicine. It's especially useful for those who can't tolerate steroids or seek a biological, root-cause solution to chronic inflammation.
Evidence grades and traditional-use labels are explained in our methodology. Nothing here is medical advice.
What it is typically used for, usual dose, cautions, and the study behind it where real trial data exists.
One email with the summary. We'll also send a short weekly evidence update — unsubscribe any time.